Myriad Genetics And Leading Cancer Center Collaborate To Study The Use Of Minimal Residual Disease Testing In Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics (NASDAQ:MYGN) has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer. The research will use Myriad's MRD testing platform, a high-definition assay that uses whole-genome sequencing for circulating tumor DNA. The study will investigate the use of MRD testing for patients in two breast cancer cohorts, focusing on treatment response prediction.
September 18, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics' collaboration with MSK to study the use of MRD testing in breast cancer could potentially enhance the company's reputation in precision medicine and genetic testing. The success of the study could lead to increased demand for Myriad's MRD testing platform.
The collaboration with MSK, a leading cancer center, could enhance Myriad Genetics' credibility in the field of genetic testing and precision medicine. If the study proves successful, it could lead to increased demand for Myriad's MRD testing platform, potentially driving up the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100